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Myelofibrotic transformation in essential
thrombocythemia. Author reply
We thank Juergen Thiele and Hans Kvasnicka for com-
menting on our recently published paper including 605
patients with essential thrombocythemia (ET).1 We pro-
vided evidence that progression to myelofibrosis (post-
ET MF) has a prevalence of 2.8% (10-year risk of 3.9%),
and that progression to acute leukemia (AL) has a preva-
lence of 2.3% (10-year risk of 2.6%). The first question
of Thiele and Kvasnicka concerns the evolution of ET in
post-ET MF and AL. They asked that the prevalence of
post-ET MF and AL in patients diagnosed according to
the PVSG criteria2 and with the WHO criteria,3 be evalu-
ated separately. The analysis suggested would be strong-
ly biased by the fact that PVSG-classified patients have
longer follow-up than WHO-classified patients. In the
paper, we mentioned that the longer the follow-up, the
higher the risk of transformation into myelofibrosis or
leukemia. We regret that their request could not be sat-
isfied, but a direct comparison of these two cohorts with
different follow-up may give a misleading message. The
second question from Thiele and Kvasnicka concerns the
diagnostic differentiation between ET and
prefibrotic/early fibrotic phase of primary myelofibrosis
(PMF), an entity recognized on the basis of bone marrow
features by the WHO classification of 2001.4 However,
the recent WHO classification requires the combination
of histological picture, clonal markers and clinical param-
eters to diagnose PMF at prefibrotic or fibrotic phase.3 In
our series we excluded cases of PMF (excluded combina-
tion of leukoerythroblastosis, anemia, elevated LDH,
spleen enlargement). Concerning the discussion on
sequential bone marrow evaluations, we perform bone
marrow biopsy at diagnosis in all the patients and during
follow-up when we suspect clinical progression of the
disease. We are glad to know that the prevalence of
myelofibrosis reported by Thiele and Kvasnicka ranges
between 2.8% and 3.5%. We find that this is a reassur-
ingly low prevalence for patients with ET. 
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A JAK2-V617F activating mutation in addition to
KIT and FLT3 mutations is associated with 
clinical outcome in patients with t(8;21)(q22;q22)
acute myeloid leukemia
A JAK2-V617F mutation was found in 3 of 45 (6.7%)
patients with t(8;21) acute myeloid leukemia (AML),
whereas only one of 137 (0.7%) patients with de novo
AML other than t(8;21) had the same mutation (p=0.047).
We examined the clinical significance of KIT, FLT3 and
JAK2 mutations as a collective group. There was a signif-
icant difference in the cumulative incidence of relapse:
77% in the 21 patients with the mutations and 26% in 19
lacking mutations respectively (p=0.0083). Our study
highlights the importance of JAK2 mutations in addition
to KIT and FLT3 mutations as a prognostic factor in
t(8;21) AML patients.
RUNX1(AML1)-RUNX1T1(MTG8) generated by
t(8;21)(q22:q22) contributes to leukemic transformation,
but additional events are required for full leukemogene-
sis.1,2 Mutations in the receptor tyrosine kinases (RTK)
including the KIT and FLT3 genes are the genetic events
that appear to cause acute myeloid leukemia (AML) har-
boring t(8;21) and are associated with unfavorable prog-
nosis.3,4 The activating missense mutation in the pseudo-
kinase domain of the JAK2 cytoplasmic tyrosine kinase
has been identified in a significant proportion of patients
with myeloproliferative disorders.5 Although the same
somatic mutation has been found in a small number of
AML patients, a relatively high incidence of JAK2-V617F
mutation is often seen in de novo and therapy-related
t(8;21) AML patients.6-10 Nevertheless, whether JAK2-
V617F mutation is associated with other biological
parameters including clinical prognosis in patients with
t(8;21) AML remains to be fully determined.
To examine its biological and prognostic impact, we
studied the JAK2 mutation in 45 patients with de novo
t(8;21) AML. Approval for this study was obtained from
the Institutional Review Board of Kumamoto University
School of Medicine. The results of KIT, FLT3, N-RAS, K-
RAS and PDGFRα mutations in 37 of the 45 patients have
been reported previously.3 Of the 45 patients, activating
mutations in KIT and internal tandem duplications in
FLT3 were observed in 18 (40%) and 3 (6.7%) respective-
ly. Mutations of JAK2-V617F were identified by allele spe-
cific RT-PCR and direct sequencing.11 We detected the het-
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erozygous JAK2-V617F mutation in 3 patients (6.7%)
with t(8;21) AML, which was consistent with previous
studies.6-10 None of the 3 t(8;21) AML patients had a his-
tory of previous myeloproliferative disorders. No muta-
tions other than V617F were found in the exons 12-14 of
JAK2. Among 137 patients with de novo AML other than
t(8;21), there was only one patient who had JAK2 muta-
tion (p=0.047). This patient had M2 with
46,XY,add(7)(q11),del(20)(q13). Thus, the present study
confirmed that the JAK2 mutation is highly associated
with t(8;21) AML.
Although the occurrence of KIT and FLT3 mutations
was mutually exclusive in t(8;21) AML patients,3 one
patient harboring a JAK2 mutation also had a KIT muta-
tion and the other patient had a K-RAS mutation (Table
1). Although we cannot exclude the possibility that two
different subclones in leukemic cells had each mutation, it
is also likely that the same leukemic cells carry both muta-
tions because heterozygous JAK2 and KIT or K-RAS
mutations are identified as equivocal peaks in the electro-
pherogram of direct sequencing (data not shown). It is of
note that a high prevalence of co-operating mutations of
FLT3, KIT, or N-RAS in AML patients with the JAK2
mutation has been reported.7-9 In the current study, a total
of 23 (51%) patients had mutations in KIT, FLT3 and
JAK2, suggesting that activating mutations in the RTK and
JAK2 play a critical role as a secondary event leading to
the development of t(8;21) AML.
We examined the clinical significance of KIT, FLT3
and JAK2 mutations as a collective group because the
present study was limited to a small number of JAK2
mutated cases for the comparison of clinical features,
and these mutations activate the same STAT signal
transduction pathway and belong in the same class I
mutation.2 There was no significant relationship
between the mutations and age, sex, leukocyte counts,
platelet counts, CD56 expression, or additional chromo-
somal aberrations. However, t(8;21) AML patients with
an activating mutation in KIT, FLT3 and JAK2 had sig-
nificantly greater marrow blast percentages and serum
lactate dehydrogenase levels than those without a
mutation (data not shown). Considering that the JAK2
mutation confers a proliferative and survival advantage
on hematopoietic cells,5 these clinical profiles appear to
be associated with these mutations.
A total of 44 patients received intensive chemotherapy
based on the Japan Adult Leukemia Study Group (JALSG)
protocols in the AML87, AML89, AML92, AML95 and
AML97 studies.12 Although patients were treated with dif-
ferent schedules, all received regimens consisting of
anthracyclines and cytarabine as induction therapy.
Cytarabine plus one of the anthracyclines, high-dose
cytarabine, or allogeneic hematopoietic stem cell trans-
plantation (HSCT) was used as post-remission therapy.
Patient 1 carrying both KIT and JAK2 mutations did not
respond to multiple induction chemotherapies including
high-dose cytarabine therapy (Table 1). Patient 2 with the
JAK2 and K-RAS mutations achieved a complete remis-
sion (CR) but later relapsed. Patient 3 received allogeneic
HSCT during the first CR and continued in CR. Twenty-
one out of 23 (91%) patients with the mutations achieved
CR, while 19 out of 21 (90%) patients lacking mutations
obtained CR (p=0.9240). On the other hand, there was a
significant difference in the cumulative incidence of
relapse: 77% in the 21 patients with the mutations and
26% in 19 lacking mutations respectively (p=0.0083)
(Figure 1A). It is likely that the poor outcome cannot be
attributable only to JAK2 mutation in patients with a KIT
or K-RAS mutation although JAK2 mutation together
with other mutations may confer additive effects on the
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Table 1. Clinical profiles of t(8;21) acute myeloid leukemia patients
harboring the JAK2 mutation.
Patient N. 1 2 3
JAK2 V617F V617F V617F
KIT N822Y - -
K-RAS - G12D -
Age (years) 31 68 26
Sex Male Female Female
Hemoglobin (g/dL) 6.9 8.1 7.1
Platelet (x109/L) 13 57 15
Leukocyte (x109/L) 43.9 30 32
Circulating blast (%) 35 18 78
Marrow blast (%) 22.5 40 NT
WBC indexa 9.88 12 NT
LDH (U/L)b 1,829 2,398 1,120
CD56 expression + + NT
Additional chromosome
abnormality add(7)(q22) - -X
Induction Failure CR CR
Relapse-free survival (years) 0 1.4 12.0+
Overall survival (years) 1.3 1.8 12.0+
aLeukocyte count x marrow blast, bNormal range of lactate dehydrogenase is 112 -
213 U/L.NT: not tested,CR: complete remission.
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Figure 1. Cumulative incidence of relapse (A) and overall survival
(B) in patients with t(8;21) acute myeloid leukemia by mutations
in KIT, FLT3 and JAK2. Estimation of survival distributions was per-
formed using the Kaplan–Meier method and the differences were
compared using the log-rank test.
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clinical outcome. Illmer et al.8 also showed that 4 of 5
t(8;21) or inv(16) AML patients with a JAK2 mutation had
early relapses within 20 months after diagnosis. Taken
together, these results suggest that mutations in the JAK2,
KIT and FLT3 genes are associated with unfavorable clin-
ical outcome in patients with t(8;21) AML.
Our study also implies that patients with RTK and JAK2
mutations may benefit from allogeneic HSCT. Three
patients with mutations received allogeneic HSCT after
relapse and have achieved continuous second CR. Three
patients in each group also received allogeneic HSCT at
the first CR. As a consequence, 6 out of 9 patients with
AML harboring KIT, FLT3 and JAK2 mutations who con-
tinued CR received allogeneic HSCT. When patients who
underwent HSCT were censored at the date of the HSCT,
the 6-year overall survival in patients with mutations was
25% compared to 62% in those without mutations
(p=0.1368) (Figure 1B). These findings are of significant
clinical import as activating mutations in KIT, FLT3 and
JAK2 could be potential therapeutic targets for specific
tyrosine kinase inhibitors and JAK2 pathway inhibitors in
patients with t(8;21) AML harboring the mutations.
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JAK1 mutation analysis in T-cell acute 
lymphoblastic leukemia cell lines
T-cell acute lymphoblastic leukemia (T-ALL) is a
malignancy of T-cell precursors that mainly occurs in
children and adolescents. A variety of oncogenic events
that are involved in the pathogenesis of T-ALL have
been identified, including NOTCH1 and PTEN muta-
tions, overexpression of TAL1, LYL1 and TLX1, and
deletion of CDKN2A (p16).1 Apart from mutations in
FLT3 and NRAS, and chromosomal aberrations generat-
ing the NUP214-ABL1 fusion, mutations that drive pro-
liferation and survival of T-ALL cells are still unknown
in the majority of patients. Recently, activating point
mutations in the JAK1 gene were identified in patients
with ALL, and rarely also in acute myeloid leukemia
(AML) patients.2-4 In T-ALL, JAK1 mutations were iden-
tified in approximately 20% of adult T-ALL cases, with
a much lower frequency in childhood T-ALL.2 These
mutations are very heterogeneous in the sense that they
are dispersed over several JAK1 domains, and differ in
their ability to transform hematopoietic cells and to acti-
vate downstream signaling pathways such as the STAT,
PI3K and MAPK cascades.2-4 
Leukemia cell lines with mutations in FLT3, JAK2 and
NOTCH1 have been described as useful models for pre-
clinical testing of small molecule inhibitors.5-8 Given the
recent identification of JAK1 mutations in T-ALL, we
investigated if JAK1 mutations could be detected in a
panel of 18 common T-ALL cell lines. By sequencing of
the JAK1 open reading frame at cDNA level in these cell
lines, we identified 2 transcript variants, one non-syn-
onymous substitution, as well as several synonymous
substitutions (Table 1). 
A first transcript variant was identified in the HPB-
ALL cell line (Figure 1A, 1B). This transcript lacks
nucleotides 2896-2967, encoding amino acids 966-989
that are located between the P-loop and the activation
loop in the kinase domain. When sequencing HPB-ALL
genomic DNA, we could not detect the presence of a
deletion, but we detected a single nucleotide change
(2897 A>T) generating a novel GT splice donor site in
haematologica | 2009; 94(3) | 435 |
©F
er
ra
ta
 S
to
rti
 F
ou
nd
at
ion
